ArticleFrontiers in psychiatry2025
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.Journal of psychopharmacology (Oxford, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: People with a history of psychotic disorders are excluded from contemporary trials of psychedelic-assisted therapy. Although survey studies have explored the impact of naturalistic psychedelic use on people with a history of psychotic disorders, a qualitative study has yet to examine the subjective effects of psychedelic use in this population during both the acute effects and perceived long-term impacts. Method: Two semi-structured in-depth interviews were conducted with participants (n = 19) who had used psychedelics after the diagnosis of non-affective psychotic disorders (NAPD). Interviews probed the perceived positive and negative effects of psychedelic use. Data were analyzed using reflexive thematic analysis. Results: We constructed three major themes: 1) common challenges during the acute effects of psychedelics; 2) psychosis-specific psychedelic experiences; and 3) post-acute and long-term effects. In the common challenges of psychedelic use theme, participants often described experiences with transient anxiety, which sometimes resulted in brief self-reported hospitalizations. In the psychosis-specific psychedelic experiences theme, the subthemes consisted of psychedelics during and after psychosis, self-compassion and reduced self-stigma, and insight into hallucinations and delusions. The post-acute and long-term effects theme included subthemes of positive effects, negative effects, and a lack of long-term effects. Overall, most participants described some benefits of psychedelics, but the durability of perceived benefits varied widely. Conclusion: Psychedelics might have heterogeneous impacts on people with NAPD, including both risks for harm and potential benefits. Our findings may assist in the development of safety and tolerability trials, highlighting the need for more nuanced work that examines how psychedelics impact people with NAPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.